Toward Efficient Trials in Colorectal Cancer: The ARCAD Clinical Trials Program

被引：27

作者：

de Gramont, Aimery ^{[1
]}

Haller, Daniel G. ^{[2
]}

Sargent, Daniel J. ^{[3
]}

Tabernero, Josep ^{[4
]}

Matheson, Alastair ^{[5
]}

Schilsky, Richard L. ^{[6
]}

机构：

[1] Hop St Antoine, F-75571 Paris, France

[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[3] Mayo Clin, Canc Ctr Stat, Rochester, MN USA

[4] Vall Hebron Univ Hosp, Med Oncol Serv, Barcelona, Spain

[5] Fdn ARCAD, Paris, France

[6] Univ Chicago, Div Biol Sci, Chicago, IL 60637 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 04期

关键词：

FLUOROURACIL PLUS LEUCOVORIN; PROGRESSION-FREE SURVIVAL; INDIVIDUAL PATIENT DATA; END-POINTS; 1ST-LINE TREATMENT; ORAL CAPECITABINE; CRITICAL PATH; COLON-CANCER; IRINOTECAN; DRUG;

D O I：

10.1200/JCO.2009.25.2544

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：527 / 530

页数：4

共 38 条

[1] ABRAMS JD, 2007, CANC CLIN TRIALS PRO, P32
[2] The biomarkers consortium: On the critical path of drug discovery
Altar, C. A.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (02) : 361 - 364
[3] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Amado, Rafael G.
Wolf, Michael
Peeters, Marc
Van Cutsem, Eric
Siena, Salvatore
Freeman, Daniel J.
Juan, Todd
Sikorski, Robert
Suggs, Sid
Radinsky, Robert
Patterson, Scott D.
Chang, David D.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) : 1626 - 1634
[4] Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer
Burzykowski, Tomasz
Buyse, Marc
Piccart-Gebhart, Martine J.
Sledge, George
Carmichael, James
Lueck, Hans-Joachim
Mackey, John R.
Nabholtz, Jean-Marc
Paridaens, Robert
Biganzoli, Laura
Jassem, Jacek
Bontenbal, Marijke
Bonneterre, Jacques
Chan, Stephen
Basaran, Gul Atalay
Therasse, Patrick
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) : 1987 - 1992
[5] Progression-free survival is a surrogate for survival in advanced colorectal cancer
Buyse, Marc
Burzykowski, Tomasz
Carroll, Kevin
Michiels, Stefan
Sargent, Daniel J.
Miller, Langdon L.
Elfring, Gary L.
Pignon, Jean-Pierre
Piedbois, Pascal
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5218 - 5224
[6] Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer
Carmichael, J
Popiela, T
Radstone, D
Falk, S
Borner, M
Oza, A
Skovsgaard, T
Munier, S
Martin, C
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) : 3617 - 3627
[7] Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study
Chibaudel, Benoist
Maindrault-Goebel, Frederique
Lledo, Gerard
Mineur, Laurent
Andre, Thierry
Bennamoun, Mostepha
Mabro, May
Artru, Pascal
Carola, Elisabeth
Flesch, Michel
Dupuis, Olivier
Colin, Philippe
Larsen, Annette K.
Afchain, Pauline
Tournigand, Christophe
Louvet, Christophe
de Gramont, Aimery
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) : 5727 - 5733
[8] Meta-analyses of adjuvant therapies for women with early breast cancer: the Early Breast Cancer Trialists' Collaborative Group overview
Clarke, M.
[J]. ANNALS OF ONCOLOGY, 2006, 17 : X59 - X62
[9] Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer
Cocconi, G
Cunningham, D
Van Cutsem, E
Francois, E
Gustavsson, B
van Hazel, G
Kerr, D
Possinger, K
Hietschold, SM
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (09) : 2943 - 2952
[10] Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
de Gramont, A
Figer, A
Seymour, M
Homerin, M
Hmissi, A
Cassidy, J
Boni, C
Cortes-Funes, H
Cervantes, A
Freyer, G
Papamichael, D
Le Bail, N
Louvet, C
Hendler, D
de Braud, F
Wilson, C
Morvan, F
Bonetti, A
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) : 2938 - 2947

← 1 2 3 4 →